Pharminent · Daily Brief
FDA approves Sanofi’s Infilbray for Gaucher disease type 3
Sanofi’s Infilbray (venglustat), a brain-penetrating small molecule, has been approved by the FDA for the treatment of Gaucher disease type 3. It is the first FDA-approved therapy for the neurological symptoms of the rare enzyme deficiency.
MedCity News →$SNYFDA approves Regeneron’s RNAi drug Livsayis in myasthenia gravis
The FDA approved Regeneron’s Livsayis (cemdisiran), an siRNA therapy for generalized myasthenia gravis developed through a collaboration with Alnylam. It is Regeneron’s first marketed RNAi drug.
BioPharma Dive →$REGN$ALNYRecursion secures FDA alignment on phase 3 endpoint for FAP therapy
Recursion’s CEO detailed a novel phase 3 endpoint for the company’s familial adenomatous polyposis therapy, saying the biotech has secured FDA alignment on the pivotal trial design. The study is planned to start in 2027.
Pharmaceutical Technology →Insmed shares jump 20% on reported Sanofi takeover interest
Insmed’s shares rose 20% on rumors that Sanofi is considering a takeover of the company, while Sanofi’s stock fell 2%. Analysts backed the rationale for a potential deal.
Pharmaceutical Technology →$SNY$INSMProstate Progress expands through alliance with Macmillan Cancer Support
Prostate Progress, a data-powered project seeking better tests, treatments and care for prostate cancer, is expanding through an alliance with Macmillan.
Pharmaphorum →Large drugmakers tell House panel they will halt some China trials
Large drugmakers told a U.S. House committee that they will halt clinical trials at some hospitals in China.
STAT →USPTO institutes Amneal, Kashiv IPR on Genentech omalizumab patent
On November 10, 2026, the U.S. Patent and Trademark Office granted institution of inter partes review in IPR2026-00260, filed by Amneal Pharmaceuticals and Kashiv BioSciences against U.S. Patent No. 12,030,959, owned by Genentech and Novartis.
Big Molecule Watch →$RHHBY$NVSGet the signal in your inbox
Sign up free →Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.